Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Crossref dates: July 17, 2021. Publisher notice ↗
Citation-backed change ledger
What changed recently?
Follow records added to PeptideScanner separately from revised profiles, corrections, and retractions. Every event keeps its date, before-and-after state, preserved version links, and supporting public sources.
2664Ledger events
2625Record additions
39Version changes
August 25, 2026Latest change date
Source-published notices
Research integrity connected to synthesis
These are Crossref-attributed publisher or Retraction Watch notices, not PeptideScanner corrections. The source-event dates and PeptideScanner review date remain separate.
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Crossref dates: December 17, 2025 and February 1, 2026. Publisher notice ↗
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial
Crossref dates: March 1, 2022. Publisher notice ↗
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
Crossref dates: February 1, 2023. Publisher notice ↗
Preserved version history
Profile and record changes
These are the latest routine updates, status changes, corrections, and retractions. Before-and-after fields are derived from adjacent preserved public versions.
Profile status changed
TB-500 profile
We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.
- PeptideScanner change date
- July 29, 2026
- Evidence lane
- Profile
Status
- Before
- FDA identity record only; approval status not established
- After
- FDA compounding safety review; final determination pending
Status classification
- Before
- identity-only
- After
- safety-review
Topic
- Before
- Identity records
- After
- Safety records
Profile summary
- Before
- A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.
- After
- A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
Evidence note
- Before
- FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.
- After
- FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
Cited source records
- Before
- fda-tb-500-identity
- After
- fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026
Named organizations
- Before
- U.S. Food and Drug Administration [sources: fda-tb-500-identity]
- After
- U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]
Claim citations
- Before
- name: fda-tb-500-identity; aliases: fda-tb-500-identity; category: fda-tb-500-identity; status: fda-tb-500-identity; summary: fda-tb-500-identity; evidenceNote: fda-tb-500-identity
- After
- name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026
Profile updated
BPC-157 profile
We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications.
- PeptideScanner change date
- July 29, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A research peptide with FDA compounding records and a recent trial-registry entry.
- After
- A research peptide represented by FDA compounding-review material and one selected trial-registry record.
Evidence note
- Before
- FDA's 2026 briefing says BPC-157 is not a component of an FDA-approved drug and describes limited safety information and characterization concerns. ClinicalTrials.gov also lists a recruiting study; registration is not proof of effectiveness.
- After
- FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.
Cited source records
- Before
- fda-bpc-157-briefing, fda-bulk-peptide-risks, ctg-nct07437547-v1
- After
- fda-bpc-157-briefing, fda-bulk-peptide-risks, ctg-nct07437547-v1, fda-pcac-peptide-meeting-2026
Named organizations
- Before
- U.S. Food and Drug Administration [sources: fda-bpc-157-briefing]; Hudson Biotech [sources: ctg-nct07437547-v1]
- After
- U.S. Food and Drug Administration [sources: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026]; Hudson Biotech [sources: ctg-nct07437547-v1]
Claim citations
- Before
- name: fda-bpc-157-briefing; aliases: fda-bpc-157-briefing; category: fda-bpc-157-briefing, fda-bulk-peptide-risks; status: fda-bpc-157-briefing; summary: fda-bulk-peptide-risks, ctg-nct07437547-v1; evidenceNote: fda-bpc-157-briefing, ctg-nct07437547-v1
- After
- name: fda-bpc-157-briefing; aliases: fda-bpc-157-briefing; category: fda-bpc-157-briefing, fda-bulk-peptide-risks, fda-pcac-peptide-meeting-2026; status: fda-bpc-157-briefing; summary: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, ctg-nct07437547-v1; evidenceNote: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026, ctg-nct07437547-v1
Profile updated
Bremelanotide profile
We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.
- PeptideScanner change date
- July 29, 2026
- Evidence lane
- Profile
Related names
- Before
- Vyleesi
- After
- Vyleesi, PT-141
Cited source records
- Before
- dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1
- After
- dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-bremelanotide-identity
Claim citations
- Before
- name: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; aliases: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; category: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; status: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; summary: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; evidenceNote: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1
- After
- name: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; aliases: fda-bremelanotide-identity; category: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; status: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; summary: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; evidenceNote: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1
Cited source
Profile updated
GHK-Cu profile
We added FDA substance-identity aliases to improve search matching. The cited compounding-list status did not change.
- PeptideScanner change date
- July 29, 2026
- Evidence lane
- Profile
Related names
- Before
- None recorded
- After
- Copper tripeptide-1, GHK copper
Cited source records
- Before
- fda-ghk-cu-503a-2026
- After
- fda-ghk-cu-503a-2026, fda-ghk-cu-identity
Claim citations
- Before
- name: fda-ghk-cu-503a-2026; aliases: fda-ghk-cu-503a-2026; category: fda-ghk-cu-503a-2026; status: fda-ghk-cu-503a-2026; summary: fda-ghk-cu-503a-2026; evidenceNote: fda-ghk-cu-503a-2026
- After
- name: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; aliases: fda-ghk-cu-identity; category: fda-ghk-cu-503a-2026; status: fda-ghk-cu-503a-2026; summary: fda-ghk-cu-identity, fda-ghk-cu-503a-2026; evidenceNote: fda-ghk-cu-503a-2026
Cited source
Profile updated
Liraglutide profile
We added a product-name lookup term that the cited FDA label communication connects to liraglutide. The profile's status did not change.
- PeptideScanner change date
- July 29, 2026
- Evidence lane
- Profile
Related names
- Before
- None recorded
- After
- Saxenda
Cited source records
- Before
- dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6
- After
- dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6, fda-glp1-label-warning-request-2026
Claim citations
- Before
- name: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; aliases: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; category: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; status: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; summary: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; evidenceNote: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6
- After
- name: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; aliases: fda-glp1-label-warning-request-2026; category: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; status: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; summary: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6; evidenceNote: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6
Profile updated
MOTS-c profile
We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review.
- PeptideScanner change date
- July 29, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A mitochondrial-derived peptide included in an FDA compounding-risk record.
- After
- A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.
Evidence note
- Before
- FDA's compounding-risk page says it has not identified human exposure data for drug products containing MOTS-c and lacks important safety information.
- After
- FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
Cited source records
- Before
- fda-bulk-peptide-risks
- After
- fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026
Named organizations
- Before
- U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]
- After
- U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026]
Claim citations
- Before
- name: fda-bulk-peptide-risks; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks; status: fda-bulk-peptide-risks; summary: fda-bulk-peptide-risks; evidenceNote: fda-bulk-peptide-risks
- After
- name: fda-mots-c-briefing; aliases: fda-mots-c-briefing; category: fda-bulk-peptide-risks, fda-mots-c-briefing; status: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; summary: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026; evidenceNote: fda-mots-c-briefing, fda-pcac-peptide-meeting-2026
Profile updated
Semaglutide profile
We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.
- PeptideScanner change date
- July 29, 2026
- Evidence lane
- Profile
Related names
- Before
- Wegovy
- After
- Wegovy, Ozempic, Rybelsus
Cited source records
- Before
- dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026
- After
- dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026, fda-semaglutide-identity
Claim citations
- Before
- name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19
- After
- name: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; aliases: fda-semaglutide-identity; category: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; status: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19; summary: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19, fda-semaglutide-2026; evidenceNote: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19
Cited source
Profile updated
Tirzepatide profile
We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.
- PeptideScanner change date
- July 29, 2026
- Evidence lane
- Profile
Related names
- Before
- Zepbound
- After
- Zepbound, Mounjaro
Cited source records
- Before
- dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023
- After
- dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023, fda-tirzepatide-identity
Claim citations
- Before
- name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; aliases: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38
- After
- name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38
Cited source
Profile updated
Abaloparatide profile
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A parathyroid hormone-related peptide analogue represented in U.S. drug-label records.
- After
- A parathyroid hormone-related peptide analogue. This profile cites a U.S. label record.
Profile updated
Afamelanotide profile
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A melanocortin analogue represented in current U.S. drug-label records.
- After
- A melanocortin analogue. This profile cites a U.S. label record.
Profile updated
Amycretin profile
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- An amylin and GLP-1 receptor agonist candidate represented in ClinicalTrials.gov.
- After
- An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
Profile updated
Bremelanotide profile
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A melanocortin receptor agonist peptide represented by one exact U.S. label record.
- After
- A melanocortin receptor agonist peptide. This profile cites a U.S. label record.
Profile updated
Cagrilintide profile
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A long-acting amylin analogue represented in ongoing ClinicalTrials.gov records.
- After
- A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.
Profile updated
Dulaglutide profile
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A GLP-1 receptor agonist represented by one exact current U.S. label record.
- After
- A GLP-1 receptor agonist. This profile cites a Trulicity label.
Profile updated
Elamipretide profile
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A mitochondria-targeting peptide candidate represented in ClinicalTrials.gov.
- After
- A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.
Profile updated
Exenatide profile
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A GLP-1 receptor agonist represented by one exact U.S. label record.
- After
- A GLP-1 receptor agonist. This profile cites a U.S. label record.
Profile updated
Glucagon profile
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A peptide hormone represented by one exact current U.S. emergency-treatment label record.
- After
- A peptide hormone. This profile cites a U.S. emergency-treatment label.
Profile updated
Insulin glargine-aldy profile
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
- PeptideScanner change date
- July 27, 2026
- Evidence lane
- Profile
Profile summary
- Before
- A long-acting insulin analogue represented by one exact current U.S. prescription-label record.
- After
- A long-acting insulin analogue. This profile cites a U.S. prescription label.
Collection activity
Recently added evidence records
These records entered PeptideScanner most recently. Their separately labeled cited source dates may be much older.
Record added
FDA enforcement report D-0058-2023
FDA's dated enforcement report D-0058-2023 lists Class I and source status Terminated for Viatris Inc. PeptideScanner connects the report to reviewed application ANDA079198 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- November 16, 2022
- Evidence lane
- Safety
Record added
FDA enforcement report D-0290-2026
FDA's dated enforcement report D-0290-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- January 21, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0404-2026
FDA's dated enforcement report D-0404-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- April 1, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0405-2026
FDA's dated enforcement report D-0405-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- April 1, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0406-2026
FDA's dated enforcement report D-0406-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- April 1, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0417-2021
FDA's dated enforcement report D-0417-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA202811 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- June 2, 2021
- Evidence lane
- Safety
Record added
FDA enforcement report D-0422-2026
FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- April 15, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0423-2026
FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- April 15, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0519-2026
FDA's dated enforcement report D-0519-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- May 13, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0536-2021
FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- June 2, 2021
- Evidence lane
- Safety
Record added
FDA enforcement report D-0541-2026
FDA's dated enforcement report D-0541-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA215421 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- May 27, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0618-2021
FDA's dated enforcement report D-0618-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA206321 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- April 21, 2021
- Evidence lane
- Safety
Record added
FDA enforcement report D-0622-2021
FDA's dated enforcement report D-0622-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA022341 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- April 21, 2021
- Evidence lane
- Safety
Record added
FDA enforcement report D-0723-2026
FDA's dated enforcement report D-0723-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA214457 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- July 8, 2026
- Evidence lane
- Safety
Record added
FDA enforcement report D-0773-2021
FDA's dated enforcement report D-0773-2021 lists Class II and source status Terminated for Eli Lilly & Company. PeptideScanner connects the report to reviewed application BLA125469 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- September 1, 2021
- Evidence lane
- Safety
Record added
FDA enforcement report D-0884-2022
FDA's dated enforcement report D-0884-2022 lists Class II and source status Completed for Cardinal Health Inc. PeptideScanner connects the report to reviewed application BLA125469 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- May 25, 2022
- Evidence lane
- Safety
Record added
FDA enforcement report D-1178-2023
FDA's dated enforcement report D-1178-2023 lists Class III and source status Terminated for Tolmar, Inc. PeptideScanner connects the report to reviewed application NDA021379 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- October 4, 2023
- Evidence lane
- Safety
Record added
FDA enforcement report D-1287-2014
FDA's dated enforcement report D-1287-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- May 7, 2014
- Evidence lane
- Safety
Record added
FDA enforcement report D-1288-2014
FDA's dated enforcement report D-1288-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- May 7, 2014
- Evidence lane
- Safety
Record added
FDA enforcement report D-1289-2014
FDA's dated enforcement report D-1289-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020263 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- May 7, 2014
- Evidence lane
- Safety
Record added
FDA enforcement report D-1290-2014
FDA's dated enforcement report D-1290-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020708 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- May 7, 2014
- Evidence lane
- Safety
Record added
FDA enforcement report D-1291-2014
FDA's dated enforcement report D-1291-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
- PeptideScanner change date
- August 25, 2026
- Cited source date
- May 7, 2014
- Evidence lane
- Safety
Record added
Abaloparatide DailyMed SPL version 1
DailyMed lists Structured Product Labeling version 1 for the reviewed Abaloparatide label family with a published date of 2017-05-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- May 4, 2017
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 10
DailyMed lists Structured Product Labeling version 10 for the reviewed Abaloparatide label family with a published date of 2021-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- December 30, 2021
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 11
DailyMed lists Structured Product Labeling version 11 for the reviewed Abaloparatide label family with a published date of 2022-11-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- November 10, 2022
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 12
DailyMed lists Structured Product Labeling version 12 for the reviewed Abaloparatide label family with a published date of 2022-12-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- December 28, 2022
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 13
DailyMed lists Structured Product Labeling version 13 for the reviewed Abaloparatide label family with a published date of 2023-06-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- June 28, 2023
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 15
DailyMed lists Structured Product Labeling version 15 for the reviewed Abaloparatide label family with a published date of 2023-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- November 30, 2023
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 16
DailyMed lists Structured Product Labeling version 16 for the reviewed Abaloparatide label family with a published date of 2024-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- March 8, 2024
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 18
DailyMed lists Structured Product Labeling version 18 for the reviewed Abaloparatide label family with a published date of 2025-04-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- April 11, 2025
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 19
DailyMed lists Structured Product Labeling version 19 for the reviewed Abaloparatide label family with a published date of 2026-08-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- August 17, 2026
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 2
DailyMed lists Structured Product Labeling version 2 for the reviewed Abaloparatide label family with a published date of 2017-10-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- October 10, 2017
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 4
DailyMed lists Structured Product Labeling version 4 for the reviewed Abaloparatide label family with a published date of 2018-07-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- July 27, 2018
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 5
DailyMed lists Structured Product Labeling version 5 for the reviewed Abaloparatide label family with a published date of 2018-11-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- November 1, 2018
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 6
DailyMed lists Structured Product Labeling version 6 for the reviewed Abaloparatide label family with a published date of 2019-11-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- November 26, 2019
- Evidence lane
- Regulatory
Record added
Abaloparatide DailyMed SPL version 7
DailyMed lists Structured Product Labeling version 7 for the reviewed Abaloparatide label family with a published date of 2020-11-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
- PeptideScanner change date
- August 22, 2026
- Cited source date
- November 6, 2020
- Evidence lane
- Regulatory